P-glycoprotein Breast cancer resistance protein Blood-brain barrier Blood-spinal cord barrier Pharmacoresistance ATP-binding cassette (ABC) drug efflux transporters in the CNS are predominantly localized to the luminal surface of endothelial cells in capillaries to impede CNS accumulation of xenobiotics. Inflammatory mediators and cellular stressors regulate their activity. Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of upper and lower motor neurons characterized by extensive neuroinflammation. Here we tested the hypothesis that disease-driven changes in ABC transporter expression and function occur in ALS. Given the multitude of ABC transporters with their widespread substrate recognition, we began by examining expression levels of several ABC transporters. We found a selective increase in only two transporters: P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) both at mRNA and protein levels, in the SOD1-G93A mouse model of ALS, specifically in disease-affected CNS regions. Detailed analysis revealed a similar disease-driven increase in P-gp and BCRP levels in spinal cord microvessels, indicating that their altered expression occurs at the blood spinal cord barrier. Transport activity of P-gp and BCRP increased with disease progression in spinal cord and cerebral cortex capillaries. Finally, P-gp and BCRP protein expression also increased in spinal cords of ALS patients. Preclinical drug trials in the mouse model of ALS have failed to decisively slow or arrest disease progression; pharmacoresistance imparted by ABC transporters is one possible explanation for these failures. Our observations have large implications for ALS therapeutics in humans and suggest that the obstacle provided by these transporters to drug treatments must be overcome to develop effective ALS pharmacotherapies.
Introduction
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that primarily affects motor neurons in the motor cortex, brain stem, and spinal cord. Research on ALS pathogenesis is focused on the contribution of a number of molecular mechanisms including oxidative stress, toxic protein aggregates, defective axonal transport, mitochondrial impairment, neuroinflammation and excitotoxicity (Boillée et al., 2006; Ilieva et al., 2009) . However, despite the availability of drugs that can target these mechanisms, preclinical studies using the SOD1-G93A mouse have failed to identify a drug that significantly slows disease progression or delays the onset of symptoms (Traynor et al., 2006) . Similarly, research efforts aimed at developing new effective therapeutics have been essentially ineffective in human ALS. Thus far, riluzole is the only FDA-approved drug for treatment of ALS and it exhibits marginal efficacy.
One mechanism contributing to difficulties in treating CNS diseases using pharmacotherapy (e.g., epilepsy and HIV-related neurological conditions) is the obstacle provided by the activity of ATP-binding cassette (ABC) transporters in brain barrier tissues (Löscher and Potschka, 2005) . These transporters are ATP-driven efflux pumps that exhibit remarkably broad specificity limits. In the blood-brain and blood-spinal cord barriers (BBB, BSCB), several ATP transporters face the vasculature, including P-glycoprotein (ABCB1/P-gp), breast cancer resistance protein (ABCG2/BCRP), and members of the multidrug-resistance associated protein family (ABCC/MRP) (Miller, 2010) . Together, these transporters limit entry of xenobiotics, including many therapeutic drugs, into the CNS (Neuwelt et al., 2011) .
We previously reported a disease-driven up-regulation of P-glycoprotein (ABCB1/P-gp) expression in spinal cord homogenates from the SOD1-G93A mice (Boston-Howes et al., 2008) and suggested that increased P-gp activity could account for the therapeutic failure of NDGA, a glutamate transport enhancer, which we tested in a preclinical trial in the SOD1-G93A mouse as a potential therapeutic for ALS (Boston-howes et al., 2008) . Furthermore, riluzole, which has Neurobiology of Disease 47 (2012) 194-200 
